Deciphering Metabonomics Biomarkers-Targets Interactions for Psoriasis Vulgaris by Network Pharmacology

Jiangyong Gu,Li,Dongmei Wang,Wei Zhu,Ling Han,Ruizhi Zhao,Xiaojie Xu,Chuanjian Lu
DOI: https://doi.org/10.1080/07853890.2018.1453169
IF: 5.348
2018-01-01
Annals of Medicine
Abstract:Objectives: Psoriasis vulgaris is a chronic inflammatory and immune-mediated skin disease. 44 metabonomics biomarkers were identified by high-throughput liquid chromatography coupled to mass spectrometry in our previous work, but the roles of metabonomics biomarkers in the pathogenesis of psoriasis is unclear. Methods: The metabonomics biomarker-enzyme network was constructed. The key metabonomics biomarkers and enzymes were screened out by network analysis. The binding affinity between each metabonomics biomarker and target was calculated by molecular docking. A binding energy-weighted polypharmacological index was introduced to evaluate the importance of target-related pathways. Results: long-chain fatty acids, phospholipids, Estradiol and NADH were the most important metabonomics biomarkers. Most key enzymes belonged hydrolase, thioesterase and acyltransferase. Six proteins (TNF-alpha, MAPK3, iNOS, eNOS, COX2 and mTOR) were extensively involved in inflammatory reaction, immune response and cell proliferation, and might be drug targets for psoriasis. PI3K-Akt signaling pathway and five other pathways had dose correlation with the pathogenesis of psoriasis and could deserve further research. Conclusions: The inflammatory reaction, immune response and cell proliferation are mainly involved in psoriasis. Network pharmacology provide a new insight into the relationships between metabonomics biomarkers and the pathogenesis of psoriasis.
What problem does this paper attempt to address?